EBV-specificity anti-GD2 CAR T-cell therapy (Baylor College of Medicine)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameEBV-specificity anti-GD2 CAR T-cell therapy (Baylor College of Medicine)

Drug Alias Name14g2a.zeta chimeric receptor transduced autologous EBV-specific cytotoxic T lymphocytes (Baylor College of Medicine)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionT lymphocytes stimulantsImmunostimulantsDisialoganglioside GD2 modulators

TargetsDisialoganglioside GD2

Therapy Area/IndicationsNeuroblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBaylor College Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesBaylor College Of Medicine

Inactive CompaniesN/A

Active IndicationsNeuroblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A